# How GLP-1 Drugs Like Ozempic Quiet Food Cravings
GLP-1 receptor agonists, a class of medications including Ozempic, Wegovy, and Mounjaro, work by dampening what users call "food noise." These drugs reduce constant thoughts about eating, cravings, and the mental preoccupation with food that often drives overeating.
The mechanism operates through multiple pathways. GLP-1 drugs slow gastric emptying, keeping food in the stomach longer and triggering lasting fullness signals. They also act directly on brain regions controlling hunger and reward, including the hypothalamus and areas linked to food motivation. This dual action addresses both physical and psychological hunger.
Research shows these medications produce dramatic results. Studies demonstrate weight loss of 15 to 22 percent of body weight in patients with obesity. Users consistently report the same experience. One common description: the constant mental chatter about food simply vanishes.
For parents considering these medications, understanding the distinction matters. GLP-1s differ from older weight-loss drugs. They target the actual biological drivers of appetite rather than working solely through stimulation or satiety. The "food noise" reduction happens because the brain receives different signals about hunger and reward.
Ozempic (semaglutide) was originally developed for type 2 diabetes. Wegovy is its higher-dose formulation for weight loss. Mounjaro (tirzepatide) combines GLP-1 action with additional hormone stimulation, showing even stronger weight-loss effects in trials.
Side effects exist. Nausea, vomiting, and gastrointestinal discomfort occur frequently, especially early in treatment. Some users experience "Ozempic fatigue." Weight regain happens in many patients after stopping the medication.
These drugs